ArticleRespiratory research2025
Aging-related signature stratifies LUAD prognosis and uncovers senescence-induced chemoresistance via NF-κB/RELA activation.
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is the most common subtype of lung cancer and a leading cause of cancer-related mortality worldwide. Aging has emerged as a significant risk factor for LUAD, with evidence suggesting that age-associated biological changes may influence prognosis. However, the underlying molecular mechanisms linking aging to tumor progression and therapy resistance are not fully understood.
methodsWe integrated transcriptomic data from LUAD cohorts to identify aging-related genes that are differentially expressed and associated with prognosis. Then Cox regression was utilized to establish an aging-related signature. Patients were stratified based on the signature, and we examined survival differences and transcription factor expression between groups. In vitro, cellular senescence was induced in A549 cells by bleomycin treatment, and subsequent changes in gene expression, transcription factor activity, and chemoresistance were assessed. Mechanistic studies included RNA interference and inhibitor treatment to investigate the dependence of chemoresistance on specific signaling pathways.
resultsA six-gene (H2AX, IGFBP1, CCL20, TFAP2A, TNFRSF11A, TNFRSF13C) aging-related signature was identified, stratifying patients into low- and high-risk groups with distinct overall survival outcomes. High-risk patients exhibited significantly poorer survival. Transcriptomic and protein analyses revealed that the transcription factor RELA was specifically upregulated in high-risk and senescent cells. Functional studies confirmed that induction of cellular senescence increased RELA expression, NF-κB signaling activation and conferred resistance to paclitaxel. Notably, genetic knockdown or inhibition of NF-κB signaling restored chemosensitivity in senescent tumor cells without reversing the senescent phenotype itself.
conclusionsThis study established a clinically relevant aging-related signature for risk stratification in LUAD and provides mechanistic insights into how aging-driven cellular senescence promotes chemoresistance through RELA/NF-κB pathway activation. Targeting NF-κB signaling may represent a promising therapeutic approach to overcome senescence-associated chemoresistance and improve outcomes for LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.